Page last updated: 2024-11-12
tetronic 701
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tetronic 701: series of surface-active block polymers with added hydrophilic (polyoxyethylene) and hydrophobic (polyoxypropylene) side chains to ethylene-diamine; used as a drug carrier [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 20641892 |
| CHEMBL ID | 3185417 |
| SCHEMBL ID | 15215483 |
| MeSH ID | M0059684 |
Synonyms (11)
| Synonym |
|---|
| tox21_302455 |
| dsstox_gsid_47630 |
| dsstox_cid_27630 |
| NCGC00256756-01 |
| cas-110617-70-4 |
| dsstox_rid_82462 |
| tetronic 701 |
| SCHEMBL15215483 |
| CHEMBL3185417 |
| DTXSID10860091 |
| 6,9-bis[2-(2-hydroxyethoxy)propyl]-4,11-dimethyl-3,12-dioxa-6,9-diazatetradecane-1,14-diol |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " A single intravenous administration of poloxamine-908-coated particles dramatically affected the circulation half-life and body distribution of a second subsequent dose." | ( A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Gray, T; Moghimi, SM, 1997) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Their potential for the administration of drugs by different routes and the improvement of the drug bioavailability and therapeutic effect are discussed." | ( Poloxamine-based nanomaterials for drug delivery. Alvarez-Lorenzo, C; Concheiro, A; Rey-Rico, A; Sosnik, A; Taboada, P, 2010) | 0.36 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Solutions of endotoxin free poloxamine 908 were injected daily intravenously to rats, and the effect on the degree of sequestration by the liver of I125 labelled, poloxamine 908-coated 60 nm polystyrene particles was investigated by studying effect of dosing regimen(s) and assessment of opsonic activity." | ( Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery. Armstrong, TI; Davis, SS; Illum, L; Moghimi, SM, 1997) | 0.3 |
| "After 3 or 4 days repeated dosing with poloxamine 908 (0." | ( Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery. Armstrong, TI; Davis, SS; Illum, L; Moghimi, SM, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 26.3045 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 29.2817 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 3.3115 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 66.6709 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 36.1051 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (40)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 24 (60.00) | 18.2507 |
| 2000's | 5 (12.50) | 29.6817 |
| 2010's | 10 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (4.76%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 40 (95.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||